
ACM BIOLABS ANNOUNCES BROAD PATENT FILING

Singapore, 2nd February 2018 – ACM Biolabs Pte Ltd announced today that it has filed a broad patent application covering major aspects of its polymersome-based vaccine platform. ACM Biolabs already has significant protection for its proprietary platform through its internal intellectual property, and through exclusive technology licensing agreements with ETPL¹ and NTUitive¹.

Dr. Fabien Décaillot, a Principal Scientist in ACM Biolabs and co-inventor of the recent patent application, commented: “Over the years we have had to carefully manage our time in order to not just develop our products but to also dedicate sufficient time and resources to the more basic science and understanding of our system. This balance has allowed us to continuously improve our results and get a much better insight into why the system works so well and, in some cases, its limitations. I am extremely pleased to have filed this latest application, which took a great deal of effort to get right as it is a comprehensive, and long, document that covers a variety of aspects we have found to be important to make effective vaccines with polymersomes. Of course, this is just a step in the journey to continually add to the strength of our portfolio and I anticipate additional filings in the coming months.”

1. Both as defined below.

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“ACM”) technology platform to allow its customers to develop diagnostics, therapeutics and vaccines targeting novel membrane proteins. ACM technology is being used by the world’s leading pharmaceutical companies to develop products requiring membrane proteins that are difficult or impossible to work with using traditional methods. ACM Biolabs has licensed technology from both A*STAR and NTUitive.

About ETPL

ETPL is the commercialisation arm of the Agency for Science, Technology and Research (A*STAR), Singapore’s lead agency for fostering world-class scientific research and talent. As a one-stop resource, ETPL supports A*STAR in transforming the economy through driving innovation and commercialising its research outcomes. ETPL enhances the research output of A*STAR scientists by translating their inventions and intellectual capital into marketable products, processes and services. Through shaping and facilitating licensing deals and spin-offs, ETPL actively engages industry leaders and players to commercialise A*STAR’s technologies and apply them to building ecosystems that benefit business, industry and economy.

About NTUitive

Nanyang Technological University (“**NTU**”) – NTUitive Pte Ltd (“**NTUitive**”) is the Nanyang Technological University’s innovation and enterprise company. NTUitive is responsible for the Innovation and Enterprise agenda at NTU. In addition to building an ecosystem that fosters entrepreneurship among its faculty, students, and alumni, NTUitive develops, manages, and commercialises the intellectual property assets of the University. NTUitive sees these roles as mutually complementary and synergistic. Ultimately, its activities are intended to translate knowledge into tangible socioeconomic benefit. NTU is a research-intensive University which is consistently ranked among the world’s best Universities.

Media Contact: info@ACMBiolabs.com